Objective: This review aims to elucidate the protective and therapeutic effects of Danshensu against glucocorticoid (GC)-induced bone development disorders and to systematically elaborate its underlying molecular mechanisms. The overarching goal is to provide a scientific rationale for developing novel therapeutics for this condition. Methods: We conducted a comprehensive literature review to summarize recent advances. The analysis focused on the pharmacological effects of Danshensu, encompassing its regulation of osteoblast and osteoclast function, modulation of key signaling pathways (e.g., Wnt/β-catenin, NF-κB, Nrf2/GPX4), as well as its antioxidant, anti-inflammatory, and bone microcirculation-improving properties. Results: The literature indicates that Danshensu regulates bone metabolism through multiple pathways. It effectively inhibits osteoclast activity, promotes osteoblast differentiation, mitigates oxidative stress, and improves the bone microenvironment. These beneficial effects are mediated through the regulation of several critical signaling pathways, including Wnt/β-catenin, NF-κB, and Nrf2/GPX4, demonstrating its potential in counteracting GC-induced bone development disorders. Conclusion: Danshensu demonstrates considerable promise for the prevention and treatment of GC-induced bone development disorders. Its multi-target mechanism of action offers valuable insights and new strategies for drug development. However, translational clinical application requires further investigation to determine the optimal dosage regimen, long-term safety, and definitive clinical efficacy through more in-depth preclinical and clinical studies.